Validity and reliability of Sarcopenia Quality of Life® Indonesia questionnaire in sarcopenic patients

Background:Sarcopenia significantly impairs quality of life(QoL).The Sarcopenia Quality of Life®(SarQol®)questionnaire provides a sarcopenia-specific instrument for the assessment of QoL.The aim of this study was to cross-culturally adapt the SarQol®to an Indonesian language questionnaire and to confirm its validity and reliability as a tool to measure QoL in Indonesian-speaking elderly patients with sarcopenia.Methods:This cross-sectional study translated and cross-culturally adapted the SarQol®questionnaire,followed by evaluating the psychometric properties of the final cross-culturally adapted SarQol®Indonesia questionnaire.Results:Fifty-nine elderly Indonesian subjects(29 sarcopenic and 30 nonsarcopenic)with a mean age of 72.2±6.3 years were included in this study.SarQol®Indonesia questionnaire overall provides a good discriminative value[60.61±14.34 vs.73.60±13.17,p=0.001],good internal consistency(Cronbach'sαcoefficient=0.896 and McDonald'sωcoefficient=0.906,both with good correlation to the questionnaire individual domains),acceptable construct validity,and good test-retest reliability(intraclass correlation coefficient:0.962[95%confidence interval:0.883-0.987]).Conclusions:The SarQol®Indonesia questionnaire provides a conceptual and literally equivalent questionnaire content to its original source with good discriminative value,good internal consistency,acceptable construct validity,and good test-retest reliability.The SarQol®Indonesia questionnaire is ready to be used to measure QoL in Indonesian elderly sarcopenic individuals.

Mesenchymal stem cell transplantation as a potential therapy for refractory lupus nephritis:A systematic review

Background:Lupus nephritis(LN)results in high morbidity and mortality in patients with systemic lupus erythematosus.Refractory cases of standard immunosuppressive therapy have been recorded.Mesenchymal stem cell transplantation(MSCT)shows potential use in autoimmune diseases.We aim to review MSCT in the treatment of refractory LN.Methods:Published articles were systematically extracted from the databases in May 2022.The quality of the studies was assessed using the Oxford Centre for Evidence-Based Medicine critical appraisal checklist.Results:Four studies were included.All studies recruit severe or refractory LN patients and show significant improvement in post-MSCT 24-h proteinuria.However,the improvement of renal function after MSCT is inconsistent between studies after a 1-month follow-up,with one study showing deterioration of the estimated glomerular filtration rate after 3 months and one study showing an increase in serum creatinine at 6 and 9 months.Moreover,all studies show improvement in Systemic Lupus Erythematosus Disease Activity Index scores after MSCT,while two studies show that a decrease in anti-double-stranded DNA(anti-dsDNA)levels after MSCT is only evident for up to 1-month period.Conclusions:MSCT can be effective,especially in severe or refractory LN.More randomized-controlled trials are needed to support this evidence.